Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar details
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Introduction
-
29 min
-
14 min
2. Overview of nonclinical safety assessment- Dr. Claudette L. Fuller
-
12 min
3. Biological safety testing: supporting medical device combination products- Dr. Christine L. Lanning
-
34 min
4. Regulatory guidance on toxicity testing of pharmaceuticals: ICH- Dr. John Kapeghian
-
48 min
- Basics of Non-clinical Toxicity Testing
-
20 min
6. Acute, subchronic, and chronic toxicity testing- Mr. Gregory Ruppert
-
56 min
7. Safety pharmacology in human pharmaceutical development- Dr. R. Dusty Sarazan
-
42 min
8. Genetic toxicology- Dr. Roderick Todd Bunch
-
48 min
9. Reproductive and developmental toxicology- Dr. Alan Hoberman
-
48 min
10. Juvenile toxicity testing- Dr. Alan Hoberman
- Dr. Elise Lewis
-
43 min
11. Pharmacokinetics, toxicokinetics and safety margins- Dr. Mark Rogge
-
48 min
12. Toxicity testing of impurities and metabolites- Dr. Kurt Black
- Organ System Toxicity Testing
-
38 min
13. Drug induced liver injury: a clinical perspective- Prof. Victor Navarro
-
62 min
14. Toxicology of the kidney- Prof. Lawrence Lash
-
58 min
15. Toxicology of the cardiovascular system- Dr. Peter Siegl
-
67 min
16. Toxicology of the immune system- Dr. Leigh Ann Burns Naas
-
59 min
17. Toxicology of the developing immune system- Dr. Leigh Ann Burns Naas
-
43 min
18. Hematology interpretation for toxicity studies- Dr. Nancy Everds
- New Methods for Assessing Toxicity
-
45 min
19. Introduction to toxicogenomics and example case studies- Dr. Cindy Afshari
- Special Cases for Toxicity Testing
-
46 min
-
32 min
21. Approaches to nonclinical vaccine development- Dr. Lisa Plitnick
-
54 min
22. Toxicity testing of oncology drugs: unraveling the last 15 years of progress- Dr. Krishna Allamneni
- Archived Lectures *These may not cover the latest advances in the field
-
56 min
23. Cellular and molecular toxicology- Dr. Dominic Williams
-
31 min
24. Overview of non-clinical safety assessment in drug development- Dr. Danuta Herzyk
-
42 min
-
56 min
-
22 min
27. Reproductive and developmental toxicology- Dr. Alan Hoberman
- Dr. Elise Lewis
-
13 min
28. Non-clinical toxicity testing for vaccines- Dr. Lisa Plitnick
-
36 min
29. Toxicity testing for oncology drugs- Dr. Theresa Reynolds
- Dr. Krishna Allamneni
Printable Handouts
Navigable Slide Index
- Introduction
- Overview
- Adverse drug reactions
- Mechanistic classification of drug reactions
- Classification of adverse drug reactions
- Products withdrawn from UK due to hepatotoxicity
- Drug metabolism: pharmacology - background
- Reminder: drug metabolism
- Variation in drug metabolism - toxicity
- Perhexilene maleate and CYP2D7
- Lipidosis induced by amphiphilic cationic drugs
- Prediction of variation in drug metabolism
- Off target clinical adverse drug reactions
- Drug metabolism: pharmacology - toxicity
- Immune mediated hepatotoxicity and bioactivation
- Metabolic basis of bioactivation and toxicity
- Prediction of toxic metabolites - methods
- Prediction of toxic metabolites - screens
- Screens for metabolic reactivity
- GSH conjugation
- Nucleophile traps for electrophilic intermediates
- Furosemide: hepatotoxicity (1)
- Characterisation of a reactive FS intermediate
- Trapping of FS intermediate by NAL and NAC
- Furosemide: hepatotoxicity (2)
- Screens for metabolic reactivity - covalent binding
- Covalent binding to protein
- How much covalent binding is acceptable: data
- How much covalent binding is acceptable: results
- Qualifying considerations
- Prediction of toxic metabolites - design
- 4-aminoquinoline antimalarials
- Amodiaquine: metabolism and toxicity
- 4-aminoquinolines: safety and efficacy in vitro
- Isoquine: glucuronylation
- Prediction of toxic metabolites - biology
- Acetaminophen/paracetamol
- Metabolism and toxicity of acetaminophen
- Functional consequences of adduct formation
- Mechanism of cell damage and critical proteins
- Hepatocyte: defence against drug-induced stress
- Mechanism of Nrf2-regulated gene induction
- Hepatic nuclear translocation of Nrf2 (1)
- Hepatic nuclear translocation of Nrf2 (2)
- Acetaminophen hepatotoxicity in mice
- Induction of Nrf2 by model hepatotoxins (1)
- Induction of Nrf2 by model hepatotoxins (2)
- Induction of Nrf2 by model hepatotoxins (3)
- Nrf2 activation: NAPQI
- Role of the adrenergic system
- Drug metabolism: toxicology
- Mechanism of cell damage: cell death (1)
- Mechanism of HMGB1 in acetaminophen toxicity
- Mechanism of cell damage: cell death (2)
- HMGB1 compared with serum ALT levels
- Effect of caspase inhibition: CK-18 and HMBG2
- Chain of events from drug to toxicity
- Making toxic or safe drugs
- Conclusions
Topics Covered
- Classification of adverse drug reactions
- How this relates to the chemical structure of the offending drug
- Understanding how variation in drug metabolism can contribute to clinical toxicity is important in designing pre-clinical models and screens
- Case studies of drugs which can form reactive metabolites and can irreversibly modify cellular protein
- Examples of structural modifications to chemicals containing toxicophores
- Novel and traditional serum and cellular biomarkers of adaptation, apoptosis and necrosis
Links
Series:
Categories:
Talk Citation
Williams, D. (2009, July 30). Cellular and molecular toxicology [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 14, 2024, from https://doi.org/10.69645/KPJD4996.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Dominic Williams has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
